- Home
- BCLI vs MCVT Comparison
BCLI vs MCVT Comparison
Compare BCLI & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- MCVT
- Stock Information
- Founded
- BCLI 2000
- MCVT 2007
- Country
- BCLI United States
- MCVT United States
- Employees
- BCLI N/A
- MCVT N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- MCVT Finance Companies
- Sector
- BCLI Health Care
- MCVT Finance
- Exchange
- BCLI Nasdaq
- MCVT Nasdaq
- Market Cap
- BCLI 9.8M
- MCVT 9.3M
- IPO Year
- BCLI N/A
- MCVT N/A
- Fundamental
- Price
- BCLI $1.08
- MCVT $1.84
- Analyst Decision
- BCLI Strong Buy
- MCVT
- Analyst Count
- BCLI 1
- MCVT 0
- Target Price
- BCLI $30.00
- MCVT N/A
- AVG Volume (30 Days)
- BCLI 473.4K
- MCVT 16.2K
- Earning Date
- BCLI 08-13-2025
- MCVT 08-13-2025
- Dividend Yield
- BCLI N/A
- MCVT N/A
- EPS Growth
- BCLI N/A
- MCVT N/A
- EPS
- BCLI N/A
- MCVT 0.19
- Revenue
- BCLI N/A
- MCVT $3,246,479.00
- Revenue This Year
- BCLI N/A
- MCVT N/A
- Revenue Next Year
- BCLI N/A
- MCVT N/A
- P/E Ratio
- BCLI N/A
- MCVT $9.81
- Revenue Growth
- BCLI N/A
- MCVT N/A
- 52 Week Low
- BCLI $0.72
- MCVT $1.13
- 52 Week High
- BCLI $6.45
- MCVT $3.88
- Technical
- Relative Strength Index (RSI)
- BCLI 43.20
- MCVT 50.24
- Support Level
- BCLI $1.08
- MCVT $1.77
- Resistance Level
- BCLI $1.32
- MCVT $1.91
- Average True Range (ATR)
- BCLI 0.10
- MCVT 0.08
- MACD
- BCLI -0.01
- MCVT -0.01
- Stochastic Oscillator
- BCLI 4.00
- MCVT 36.11
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.